Presbyopia
Conditions
Brief summary
Low dose compose to control presbyopia symptoms
Detailed description
A los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control presbyopia symptoms compared to pilocarpine and brimonidine in low doses.
Interventions
COMBINATION_PRODUCTPBO to control presbyopia symptoms
Low dose PBO to control presbyopia symptoms
Sponsors
Optall Vision
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
While in office the care provider took a number out of a closed container. Number 1 was designated for the placebo; Number 2 was designated for the compound
Intervention model description
Pilocarpine, brimonidine, oxymetazoline (PBO) compound was instilled in the non-dominant eye of presbyopic patients, while in the dominant eye pilocarpine or brimonidine were instilled.
Eligibility
Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy * Presbyopic * 40 - 59 years
Exclusion criteria
* Diabetics * Previous eye surgery * Previous eye disease * \> 0.50 myopia * \> 1.5 hyperopia or astigmatism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Jaeger notation near uncorrected visual acuity change | 1 hour | Number of lines improved 1 hour after drug instillation |
| Comparison of PBO compound Jaeger notation improvement vs Pilocarpine or Brimonidine alone | 1 hour | Number of lines improve comparing PBO compound vs Pilocarpine or Brimonidine |
Countries
Mexico
Outcome results
None listed